Brookline Capital Management Upgrades Cognition Therapeutics (NASDAQ:CGTX) to Strong-Buy

Cognition Therapeutics (NASDAQ:CGTX) was upgraded by research analysts at Brookline Capital Management to a “strong-buy” rating in a research report issued to clients and investors on Monday,Zacks.com reports.

Other equities analysts have also issued research reports about the stock. Chardan Capital restated a “buy” rating and set a $11.00 price target on shares of Cognition Therapeutics in a research report on Thursday, December 19th. HC Wainwright raised their price target on shares of Cognition Therapeutics from $5.00 to $6.00 and gave the stock a “buy” rating in a research note on Thursday, December 19th. Finally, B. Riley upgraded Cognition Therapeutics from a “neutral” rating to a “buy” rating and upped their price objective for the company from $1.00 to $1.50 in a research note on Thursday, December 19th. One investment analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $8.30.

Cognition Therapeutics Stock Down 5.8 %

Cognition Therapeutics stock opened at $0.71 on Monday. The company’s 50 day moving average price is $0.59 and its two-hundred day moving average price is $0.70. Cognition Therapeutics has a 52 week low of $0.34 and a 52 week high of $2.95. The stock has a market cap of $29.50 million, a P/E ratio of -0.73 and a beta of 0.95.

Institutional Trading of Cognition Therapeutics

A number of institutional investors have recently modified their holdings of the business. Mercer Global Advisors Inc. ADV raised its stake in shares of Cognition Therapeutics by 33.4% during the 2nd quarter. Mercer Global Advisors Inc. ADV now owns 95,951 shares of the company’s stock valued at $159,000 after purchasing an additional 24,050 shares during the period. Sigma Planning Corp grew its position in shares of Cognition Therapeutics by 14.6% during the 3rd quarter. Sigma Planning Corp now owns 197,190 shares of the company’s stock valued at $92,000 after purchasing an additional 25,050 shares in the last quarter. Virtu Financial LLC bought a new position in shares of Cognition Therapeutics in the third quarter worth $27,000. Finally, SG Americas Securities LLC purchased a new stake in shares of Cognition Therapeutics in the fourth quarter worth $26,000. 43.35% of the stock is currently owned by hedge funds and other institutional investors.

Cognition Therapeutics Company Profile

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.